The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 March 2026•

1 min read

US Dominates Weight-Loss Drug Market as Novo Nordisk Revenue Skyrockets

Stylized metallic devices with 'Lilly' and 'SCYNEXIS PHARMACEUTICALS' logos, surrounded by scientific equipment, molecular structures, and data charts on a golden background.

Key Facts

1Novo Nordisk's revenue from weight-management treatments grew from $1.3 billion in 2021 to approximately $12.4 billion in 2025.

The United States has emerged as the global epicenter for the GLP-1 weight-loss drug boom, driving a significant revenue surge for Novo Nordisk's obesity franchise. The company's revenue from weight-management treatments skyrocketed from $1.3 billion in 2021 to approximately $12.4 billion by 2025. Currently, the US market accounts for more than 60% of global revenue for drugs specifically marketed for weight loss. While Wegovy remains the primary driver of this growth, Ozempic is frequently utilized off-label for weight loss purposes. This concentration highlights the pharmaceutical industry's heavy reliance on robust US demand and high obesity prevalence. Analysts maintain a bullish outlook for major players like Novo Nordisk and Eli Lilly as they continue to capitalize on this rapidly expanding therapeutic segment.